Medifacts International bags $2.7 million contract with a top ten pharmaceutical company

MEDIFACTS INTERNATIONAL, INC., one of the largest global providers of noninvasive cardiac diagnostic services, today announced the award of a $2.7 million contract with a top ten pharmaceutical company to provide comprehensive cardiac safety and efficacy services for a large late stage clinical trial.

Continuing on its momentum and reaffirming its reputation of “client first,” Medifacts is demonstrating a unique ability to combine multiple technology platforms, innovative and efficient study design, and a laser focus on “the right approach” in conducting their clinical trials. Medifacts will provide consulting, equipment and an array of services for a cardiac safety study to be conducted in hundreds of sites spread over three continents.

Michael Woehler, Medifacts International’s President and Chief Executive Officer said: "We are seeing a very positive reaction to our proactive approach regarding study designs and timetables. Our technology, primarily our WebHeart^® platform, continues to set the global standard in cardiac safety and efficacy data collection, management and submission and our commitment to our sponsors’ rigorous expectations that we be the 'experts' continues to pay dividends as we advance our position as one of the top 3 global cardiac safety businesses.”